Clinical trials: Colorectal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals
Colorectal Cancer, Pancreatic Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. QS21 may improve the ability of the immune system to respond to disease. Combining vaccine therapy with QS21 may kill more tumor cells.
- Trial name
- NCT00006387
- Testing
- QS21, ras peptide cancer vaccine
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer, Gastric Cancer
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve overall survival.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT02562963
- Testing
- natural killer T cell
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Minghui Zhang
Colorectal Cancer, Colorectal Neoplasms
A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT04148378
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Colon Adenocarcinoma
Treatment and Outcomes of Stage III Colon Cancer in Patients 80 Years of Age and Older
The objective of this study was to assess survival trends in elderly patients with stage III colon cancer
- Trial name
- NCT04526314
- Testing
- observational
- Where
- France
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Registre des Tumeurs Digestives du Finistère
Colorectal Cancer, Fatigue
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers
RATIONALE: Learning about quality of life, symptoms, and health behaviors in colorectal cancer survivors may help to determine the long-term effects of colon and rectal cancer treatments and may help to improve the quality of…
- Conditions
- Colorectal Cancer, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Pain
- Trial name
- NCT00410579
- Testing
- Telephone interview
- Where
- 200 sites in United States
- Volunteers
- 744 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer, Carcinoma, Neuroendocrine
TheraSphere for the Treatment of Liver Metastases
This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be…
- Conditions
- Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
- Trial name
- NCT00511862
- Testing
- Yttrium 90 glass microspheres
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Boston Scientific Corporation
Peritoneal Carcinomatosis, Colorectal Cancer
HIPEC for Peritoneal Carcinomatosis
This is a clinical study investigating the new treatment of surgery combined with intraperitoneal mitomycin-C for patients with gastrointestinal cancer that has spread to the peritoneal (abdominal cavity) surface.
- Conditions
- Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma
- Trial name
- NCT02040142
- Testing
- HIPEC, Mitomycin C
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Albert Einstein College of Medicine
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Liver Metastases, Hepatocellular Carcinoma
Irreversible Electroporation of Unresectable Liver Tumors
The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Bile Duct Cancer
- Trial name
- NCT04404647
- Testing
- Irreversible electroporation
- Where
- Denmark
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01167725
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Where
- 2 sites in United States
- Volunteers
- 340 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Colorectal Carcinoma
Phase I FOLFOX Combination
A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal…
- Trial name
- NCT00499850
- Testing
- ZD6474 (vandetanib), 5-Fluorouracil, Leucovorin
- Where
- 4 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Genzyme, a Sanofi Company
Rectal Cancer, Non Metastatic Cancer
Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer
Until 2020, the standard treatment for rectal cancer was a combination of radiotherapy and concomitant chemotherapy based on IV or oral 5FU, with a low complete response rate.
- Trial name
- IMMUNOREC (NCT06536127)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Sainte Catherine
Colorectal Cancer
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276861
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
Colorectal Cancer, Kidney Cancer
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030342
- Testing
- recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Luke's Medical Center
Colorectal Cancer
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00081289
- Testing
- Radiation Therapy, Capecitabine 1650 mg/m^2/day, Capecitabine 1200 mg/m^2/day
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- Radiation Therapy Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.